A280V polymorphism in the histamine H3 receptor as a risk factor for migraine

Archives of Medical Research

Volumn 42, Issue 1, 2011, Pages 44-47

  Millán Guerrero, Rebeca O ^a   Baltazar Rodríguez, Luz M ^b   Cárdenas Rojas, Martha I ^b   Ramírez Flores, Mario ^b   Isais Millán, Sara ^a   Delgado Enciso, Ivan ^b   Caballero Hoyos, Ramiro ^a   Trujillo Hernández, Benjamín ^a  

^a Hospital General de Zona IMSS   (Mexico)

^b UNIVERSIDAD DE COLIMA   (Mexico)

Author keywords

A280V polymorphism; H3 receptor; H3 receptor gene; Histamine; Migraine; Risk factors

Indexed keywords

HISTAMINE H3 RECEPTOR;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; MIGRAINE; PATHOGENESIS; POLYMERASE CHAIN REACTION; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; MALE; MEXICO; MIDDLE AGED; MIGRAINE DISORDERS; POLYMORPHISM, GENETIC; RECEPTORS, HISTAMINE H3; RISK FACTORS; YOUNG ADULT;

EID: 79952083298     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.01.009     Document Type: Article

References (35)

1. Pearce J.M.S. Migraine. Eur Neurol 2005, 53:109-110.
2. Lipton R.B., Bigal M.E., Diamond M., et al. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007, 68:343-349.
3. Coppola G., Pierelli F., Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine?. Cephalalgia 2007, 27:1427-1439.
4. Peroutka S.J. Neurogenic inflammation and migraine. Implications for therapeutics. Mol Interv 2005, 5:304-311.
5. Moskowitz M.A. Defining a pathway to discovery from bench to bedside: the trigeminovascular system and sensitization. Headache 2008, 48:688-690.
6. Bakker R.A. Histamine H3-receptor isoforms. Inflamm Res 2004, 53:509-516.
7. Millan-Guerrero R.O., Isais C.M., Antonio O.A., et al. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study. Headache 1999, 39:576-580.
8. Arrang J.M., Garbarg M., Schwartz J.C. Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983, 302:832-837.
9. Ducros A., Tournier-Lasserve E., Bousser M.G. The genetics of migraine. Lancet Neurol 2002, 1:285-293.
10. Lovenberg T.W., Roland B.L., Wilson S.J., et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999, 55:1101-1107.
11. Leurs R., Bakker R.A., Timmerman H., et al. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005, 4:107-120.
12. Wellendorph P., Goodman M.W., Burstein E.S., et al. Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor. Neuropharmacology 2002, 42:929-940.
13. Bongers G., Bakker R.A., Leurs R. Molecular aspects of the histamine H3 receptor. Biochem Pharmacol 2007, 73:1195-1204.
14. Liu C., Ma X.J., Lovenberg T.W. Alternative splicing of the histamine H(3) receptor mRNA at the third cytoplasmic loop is not detectable in humans. BrainRes Mol Brain Res 2000, 83:145-150.
15. Wiedmann P., Bônisch H., Oerters F., et al. Structure of the human histamine H3 receptor gene (HRH3) and identification of naturally occurring variations. J Neural Transm 2002, 109:443-453.
16. Hancock A.A. Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci 2003, 73:3043-3072.
17. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004;24(suppl 1):1-150.
18. International Classification of Headache Disorders, Olesen J. International Classification of Headache Disorders, 2nd ed. (ICHD-2): current status and future revisions. Cephalalgia 2006, 26:1409-1410.
19. Delgado-Enciso I., Martinez-Garza S.G., Rojas-Martinez A., et al. 677T mutation of the MTHFR gene in adenomas and colorectal cancer in a population sample from northeastern Mexico. Preliminary results. Rev Gastroenterol Mex 2001, 66:322-337.
20. Hulley S.B., Gove S., Cummings S.R. Eleccion de los individuosue participaran en el estudio: especificacion y muestreo. Diseño de la Investigacion Clinica 1997, 21-55. Harcourt Brace, Spain. S.B. Hulley, S.R. Cummings (Eds.).
21. Ku M., Silverman B., Prifti N., et al. Prevalence of migraine headaches in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006, 97:226-230.
22. Aamodt A.H., Stovner L.J., Langhammer A., et al. Is headache related to asthma, hay fever, and chronic bronchitis? The Head-HUNT study. Headache 2007, 47:204-212.
23. Mansfield L.E. The role of antihistamine therapy in vascular headaches. J Allergy Clin Immunol 1990, 86(4 Pt 2):673-676.
24. Heatley R.V., Denburg J.A., Bayer N., et al. Increased plasma histamine levels in migraine patients. Clin Allergy 1982, 12:145-149.
25. Tokita S., Takahashi K., Kotani H. Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci 2006, 101:12-18.
26. Schlicker E., Malinowska B., Kathmann M., et al. Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol 1994, 8:128-137.
27. Morisset S., Rouleau A., Ligneau X., et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 2000, 408:860-864.
28. Linde M., Jonsson P., Hedenrud T. Influence of disease features on adherence to prophylactic migraine medication. Acta Neurol Scand 1998, 118:367-372.
29. Hough L.B. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 2001, 59:415-419.
30. Kara I., Ozkok E., Aydin M., et al. Combined effects of ACE and MMP-3 polymorphisms on migraine development. Cephalalgia 2007, 27:235-243.
31. Vahedi K., Depienne C., Le Fort D., et al. Elicited repetitive daily blindness. A new phenotype associated with hemiplegic migraine and SCN1A mutations. Neurology 2009, 72:1178-1183.
32. García-Martín E., Martínez C., Serrador M., et al. Histamine-N-methyl transferase polymorphism and risk for migraine. Headache 2008, 48:1343-1348.
33. Takahashi K., Tokita S., Kotani H. Generation and characterization of highly constitutive active histamine H3 receptors. J Pharmacol Exp Ther 2003, 307:213-218.
34. Parsons M.E., Ganellin C.R. Histamine and its receptors. Br J Pharmacol 2006, 147(suppl 1):S127-S135.
35. Hardy J., Singleton A. Genomewide association studies and human disease. N Engl J Med 2009, 360:1759-1768.